Minute Insight: Angle’s Parsortix Gets FDA Approval, Marking New Era For Liquid Biopsy

The FDA has approved Angle’s Parsortix circulating tumor cell cancer capturing system, which the company believes will be a paradigm shift for liquid biopsy in the US and heighten competition in the oncology diagnostics space.